Caris Life Sciences launched Caris ChromoSeq, a combined whole-genome sequencing and whole-transcriptome assay aimed at improving clinical genomic evaluation for myeloid malignancies. The test targets about 250x genome read depth and 40 million transcriptome reads from bone marrow aspirate or peripheral blood. The company positioned ChromoSeq for acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms, and expanded use to patients with suspected myeloid malignancies with persistent unexplained cytopenia after other causes are excluded. Together with similar commercialization of transcriptome-enabled platforms, the rollout underscores a continued shift from single-test genomics toward broader multi-layer profiling that can support more precise treatment selection and therapy resistance analysis.